Weight loss linked to lower inflammatory markers in women with breast cancer

Weight loss through lifestyle intervention in women with HER2-negative breast cancer showed a correlation with improved inflammatory markers. The Breast Cancer Weight Loss (BWEL) trial, presented by Dr. Jennifer A. Ligibel, included 3,180 women with stage 2 and 3 HER2-negative breast cancer. Results showed a 5.7% weight loss at 1 year led to significant improvements in metabolic hormones and inflammatory biomarkers. The study found a reduction in insulin levels, improved insulin resistance, and other metabolic markers. Continued research will determine if these changes in biomarkers translate into better breast cancer outcomes for the patients.

Source link